Evidence map›Paper›PMID 41028770›Full record

ArticleScientific reports2025

A proof of concept study of

Caozhe Cui, Jianbo Cao, Yayuan Li, Boren Jia, Ning Ma, Xiaomeng Li, Meng Liang, Mingxia Hou, Yanan Zhang, Hongliang Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Dynamic changes in serum IL-6, TNF-Frontiers in medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Caozhe CuiSpecial Medical Research Institute of Shanxi Medical University, Taiyuan, China.
Jianbo CaoCollaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan, China.
Yayuan LiSpecial Medical Research Institute of Shanxi Medical University, Taiyuan, China.
Boren JiaDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Ning MaDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Xiaomeng LiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Meng LiangDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Mingxia HouDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Yanan ZhangCollaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan, China.
Hongliang WangSpecial Medical Research Institute of Shanxi Medical University, Taiyuan, China.
Zhifang WuSpecial Medical Research Institute of Shanxi Medical University, Taiyuan, China. wuzhifang01@163.com.

Funding

National Natural Science Foundation of China NSFC 81971655Shanxi Province Graduate Research Innovation Project 2023KY366
6 · The paper itself

Abstract

This study aimed to evaluate diffuse large B-cell lymphoma (DLBCL) patients who have refractory/relapsed disease and characterize the heterogeneity of DLBCL using patient-level radiomics analysis based on

Indexed as

Fluorodeoxyglucose F18Lymphoma, Large B-Cell, DiffusePositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overAlgorithmsFemaleHumansMaleMiddle AgedProof of Concept StudyRadiomicsRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals18F-FDG PET/CTDiffuse large B cell lymphomaMachine learningRadiomics

Identifiers

PMID41028770
PMCPMC12484957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.